Posts Archive

First Posted 2020-10-19 Trial status Active, not recruiting Sponsor AstraZeneca Abstract Presentation Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). Meeting Abstract: 2025 ASCO Annual Meeting II Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary June 04, 2025 Click here for det

First Posted 2018-07-03 Trial status Active, not recruiting Sponsor Groupe Oncologie Radiotherapie Tete et Cou Abstract Presentation NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Meeting Abstract: 2025 ASCO Annual Meeting II Head and Neck Cancer - June 04, 2025 Click here for details Press Release GORTEC Announces New Trial Suc

First Posted 2017-03-27 Trial status Active, not recruiting Sponsor Sarcoma Alliance for Research through Collaboration Abstract Presentation Meeting Abstract: 2024 ASCO Annual Meeting Sarcoma - May 29, 2024 SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma. Click here for details Peer-reviewed journal publication THE LANCET Volume 404, Issue 10467p2053-2064November 23, 2024 Safety and efficacy of pembrolizuma

First Posted 2022-11-21 Trial status Recruiting Sponsor Gilead Sciences Abstract Presentation Peer-reviewed journal publication Press Release FDA NCCN NCT05633654: Phase 3: (ASCENT-05/​AFT-65 OptimICE-RD/​GBG 119/​NSABP B-63) Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With TNBC (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Hav

First Posted 2017-01-30 Trial status Completed Sponsor Merck Sharp & Dohme LLC Abstract Presentation 2019 San Antonio Breast Cancer Symposium. Abstract GS3-03. Presented December 12, 2019. Schmid P, Park YH, Ferreira M, et al: KEYNOTE-522: Phase 3 study of neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy, followed by adjuvant pembrolizumab versus placebo for early triple-negative breast cancer: Pathologic complete response in key subgroups and by treatm